TW200614990A - Methods for preparing indazole compounds - Google Patents

Methods for preparing indazole compounds

Info

Publication number
TW200614990A
TW200614990A TW094138224A TW94138224A TW200614990A TW 200614990 A TW200614990 A TW 200614990A TW 094138224 A TW094138224 A TW 094138224A TW 94138224 A TW94138224 A TW 94138224A TW 200614990 A TW200614990 A TW 200614990A
Authority
TW
Taiwan
Prior art keywords
methods
indazole compounds
compounds
preparing indazole
formula
Prior art date
Application number
TW094138224A
Other languages
Chinese (zh)
Inventor
Srinivasan Babu
Dagnino, Jr
Michael Allen Ouellette
Bing Shi
qing-ping Tian
Scott Edward Zook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200614990A publication Critical patent/TW200614990A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The invention relates to methods for preparing indazole compounds having formula I: or pharmaceutically acceptable salts or solvates thereof. Compounds of the formula I are useful as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.
TW094138224A 2004-11-02 2005-11-01 Methods for preparing indazole compounds TW200614990A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02

Publications (1)

Publication Number Publication Date
TW200614990A true TW200614990A (en) 2006-05-16

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094138224A TW200614990A (en) 2004-11-02 2005-11-01 Methods for preparing indazole compounds

Country Status (15)

Country Link
EP (1) EP1809625A1 (en)
JP (1) JP2008518901A (en)
KR (1) KR20070058689A (en)
CN (1) CN101044138A (en)
AR (1) AR051753A1 (en)
AU (1) AU2005300311A1 (en)
BR (1) BRPI0517921A (en)
CA (1) CA2586176A1 (en)
IL (1) IL182096A0 (en)
MX (1) MX2007003603A (en)
NO (1) NO20072747L (en)
RU (1) RU2007114112A (en)
TW (1) TW200614990A (en)
WO (1) WO2006048745A1 (en)
ZA (1) ZA200702317B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5528807B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド Compound drug
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
ES2439705T3 (en) * 2007-10-25 2014-01-24 Genentech, Inc. Process for the preparation of thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
CN103826618A (en) 2011-09-30 2014-05-28 辉瑞大药厂 Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
SG11201401656PA (en) 2011-11-11 2014-10-30 Pfizer N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN103387565B (en) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 Preparation method of Axitinib
CN103570696B (en) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 A kind of preparation method of Axitinib intermediate and preparing the application in Axitinib
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
EP3102605B1 (en) 2014-02-04 2018-11-14 Pfizer Inc Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
WO2015152117A1 (en) * 2014-03-31 2015-10-08 千寿製薬株式会社 Alkynyl indazole derivative and use thereof
CN104072484B (en) * 2014-07-07 2016-07-06 渤海大学 Nitrogen-(4-(aromatic thiohydroxy)-1 hydrogen-indazole-3-base)-1-(heteroaromatic replacement) methylene imine compounds and pharmaceutically acceptable salt and its preparation method and application thereof
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CA2977767A1 (en) 2015-02-26 2016-09-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent Gmbh Pd-l1 antagonist combination treatments
JP2019530704A (en) 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド Avelumab dosing regimen for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3956321B1 (en) 2019-04-18 2024-03-20 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
CN112209861A (en) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 Acixtinib intermediate compound and preparation method thereof
CN112442010B (en) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 Prodrug compounds and application thereof in treating cancers
CN111440102B (en) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 Preparation method of dithiodibenzoamide compound
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
CN114591338B (en) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 Preparation method and application of Syk and VEGFR2 double-target inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
CN1747950A (en) * 2002-12-19 2006-03-15 美国辉瑞有限公司 2-(1h-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
RU2357957C2 (en) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. P38 inhibitors and application methods
JPWO2005094823A1 (en) * 2004-03-30 2007-08-16 協和醗酵工業株式会社 Flt-3 inhibitor

Also Published As

Publication number Publication date
AR051753A1 (en) 2007-02-07
RU2007114112A (en) 2008-12-10
EP1809625A1 (en) 2007-07-25
BRPI0517921A (en) 2008-10-21
NO20072747L (en) 2007-07-31
KR20070058689A (en) 2007-06-08
JP2008518901A (en) 2008-06-05
MX2007003603A (en) 2007-05-21
CA2586176A1 (en) 2006-05-11
CN101044138A (en) 2007-09-26
IL182096A0 (en) 2007-07-24
ZA200702317B (en) 2008-09-25
AU2005300311A1 (en) 2006-05-11
WO2006048745A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
TW200614990A (en) Methods for preparing indazole compounds
IL260127B (en) Mek inhibitors and methods of their use
NO2017019I2 (en) Enzalutamide or a pharmaceutically acceptable salt thereof
IN2014KN02886A (en)
ATE532789T1 (en) DIHYDROTHIENOPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
ATE493418T1 (en) DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
TW200801008A (en) Protein kinase inhibitors
TW200607505A (en) Fused heterocyclic kinase inhibitors
ATE432281T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
MY139689A (en) Imidazotriazines as protein kinase inhibitors
UA95244C2 (en) Compounds and methods for kinase modulation, and indications therefor
TW200621721A (en) Methods of preparing indazole compounds
UA94097C2 (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MX2008001538A (en) 2-aminoaryl pyridines as protein kinases inhibitors.
ATE419249T1 (en) INHIBITORS OF MITOTIC KINESIN
NO20070589L (en) Mitotic kinesin inhibitors.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
UA96427C2 (en) Substituted pyrazole compounds
TW200630345A (en) Methods for preparing indazole compounds
TW200801020A (en) Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines
UA92047C2 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2007026221A3 (en) Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines
UA88794C2 (en) Pyrrolopyrazoles, potent kinase inhibitors